Seeking Alpha

Pluristem Therapeutics (PSTI) +8.4% premarket after it responds to a Bloomberg article that says...

Pluristem Therapeutics (PSTI) +8.4% premarket after it responds to a Bloomberg article that says the second of three patients given PSTI’s experimental stem cells died after the company touted the treatments as “life-saving." PSTI wants Bloomberg to publish a correction because the article is "factually inaccurate and misleading."
Comments (4)
  • SuzaAdam
    , contributor
    Comment (1) | Send Message
    About the Patient


    This 54 year-old patient was diagnosed with lymphoma in 2008 and received chemotherapy, resulting in remission of the disease in 2009. At that point doctors collected stem cells from her bone marrow. The cancer returned to her spinal cord in 2011. She was treated with both radiation and chemotherapy, which damaged her bone marrow. Autologous stem cell therapy was administered with cells collected from her in 2009. The bone marrow engrafted poorly and she was not responding to alternate treatments. Forty-five days after the autologous stem cell transplantation, with the patient’s clinical condition deteriorating, PLX cells were administered IM via two courses a week apart. Approximately two weeks after her second course of PLX cells, clinical improvement was noted with an increase in her red blood cells, white blood cells and platelets. Her clinical condition has improved significantly to the point that she was released from the hospital.


    In terms of clinical efficiacy, this is considered effective treatment and an improvement in the quality of life standards. She had terminal cancer, for which unfortunately no treatment exists. The pertinent facts are as follows:


    Quality of Life improvement
    Extended life expectancy
    Improvement of her medical condition with treatment - blood cell count
    9 Nov 2012, 09:12 AM Reply Like
  • User 525079
    , contributor
    Comments (102) | Send Message
    Well said.
    9 Nov 2012, 12:35 PM Reply Like
  • nooyawka212
    , contributor
    Comments (2) | Send Message
    The Bloomberg articles are examples of bad reporting. Whether there is an additional purpose to the bad reporting is worthy of investigation. As a general rule, follow the money.
    9 Nov 2012, 01:14 PM Reply Like
  • Henry McCusker
    , contributor
    Comments (4) | Send Message
    Pluristem – check your rear-view mirror – why did so many “opine” and react to the Bloomberg article? In the cell therapy universe, PSTI’s more than often “hyperbole” style has by turns been admired and derided. The “walls of reality” closed in … does this “on slot” of written matter talk about their relationships to the “street” and to the reporting thus, “transparency” is the ultimate vehicle … no matter what one does – there is a population of investors that are “moved” by perception! Maybe, there is a lesson here but, the damage is done!
    9 Nov 2012, 05:07 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs